# A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

> **NCT06100289** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 70 (estimated)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab IV
- **DRUG:** Vedolizumab SC

## Key facts

- **NCT ID:** NCT06100289
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2027-11-15
- **Final completion:** 2027-11-15
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06100289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06100289, "A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06100289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*